Onco-Innovations Ltd.
ONCO.CN
Canadian Securities Exchange0.65
CAD
+0.01
- -
Onco-Innovations Ltd.
ONCO.CN
(Canadian Securities Exchange)
Recent
price
0.65
P/E
ratio
- -
div
yld
- -
ROIC.AI
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- Similar Companies
- Business
- Onco-Innovations Ltd. (CBOE CA: ONCO) is a preclinical-stage biotechnology company focused on developing innovative cancer therapies targeting solid tumors through inhibition of DNA repair mechanisms; its lead product candidate, ONC010, comprises a proprietary nanoparticle-formulated inhibitor of polynucleotide kinase 3'-phosphatase (PNKP) designed to sensitize cancer cells to chemotherapy, radiation, and surgery by preventing DNA repair, thereby enhancing treatment efficacy and potentially reducing side effects across multiple cancer types including colorectal cancer; the company also leverages the SynoGraph AI platform acquired from Inka Health to accelerate patient identification, optimize precision oncology treatment planning, and streamline drug development pipelines. Founded on September 16, 2021, and headquartered at 1309 7th Street SW, Calgary, Alberta, Canada, Onco-Innovations holds exclusive global rights to PNKP Inhibitor Technology licensed from the University of Alberta in 2024, backed by nine issued patents from over 15 years of research, with operations centered in Canada and a focus on worldwide commercialization of oncology solutions. Recent developments include the July 2024 acquisition of Onco-Innovation and name change from Aurora Sky Ventures Corp., integration of Inka Health's AI capabilities, a November 2024 prospectus raising $2.5 million plus $1.29 million in additional funding to expand R&D, November 2025 partnerships with Dalton Pharma Services for PNKP inhibitor manufacturing optimization and scale-up toward Phase 1 trials, and with Kuano Ltd. for AI and quantum computing-enhanced drug discovery to accelerate technology advancement; the company attended the University of Alberta's 2025 Innovation Awards and advanced Inka Health's real-world evidence frameworks for health technology assessment.